VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 1, 2002, Pages 44-48

  Gu, Zhong Ping ^a   Wang, Yun Jie ^a   Li, Jin Ge ^a   Zhou, Yong An ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; COMPLEMENTARY RNA; GENE PRODUCT; LIPOFECTAMINE; PCEP AVEGF 165; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; EUKARYOTE; EXPRESSION VECTOR; FEASIBILITY STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUDE MOUSE; RECOMBINANT PLASMID; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BAGG ALBINO MOUSE; CARCINOGEN TESTING; CELL CULTURE; CELL CYCLE; ELECTRON MICROSCOPY; ESOPHAGUS TUMOR; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMID; ULTRASTRUCTURE;

ANIMALS; CARCINOGENICITY TESTS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CLONING, MOLECULAR; ENDOTHELIAL GROWTH FACTORS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RNA, ANTISENSE; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036008140     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i1.44     Document Type: Article

References (65)

1. Angiogenesis in cancer and other diseases
2. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways
3. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
4. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue
5. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis
6. Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension
7. Expression of VEGF 121 in gastric carcinoma MGC803 cell line
8. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas
9. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting
10. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases
11. Mechanisms of angiogenesis and arteriogenesis
12. Clinical applications of angiogenic growth factors and their inhibitors
13. Vascular endothelial growth factor: Molecular and biological aspects
14. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
15. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer
16. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
17. Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line
18. Acute toxicology and pharmacokinetic assessment of a ribozyme (angiozyme) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey
19. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC)
20. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
21. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
22. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice
23. Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA)
24. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea
25. Mechanisms of angiogenesis
26. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis
27. Genetic heterogeneity of angiogenesis in mice
28. Local imbalance of proangiogenic and antiangiogenic factors: A potential mechanism of focal necrosis and dormancy in tumors
29. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
30. Tumor angiogenesis: Therapeutic implications
31. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
32. Progestin regulation of vascular endothelial growth factor in human breast cancer cells
33. Role of vascular endothelial growth factor in regulation of physiological angiogenesis
34. Vascular endothelial growth factor (VEGF) and its receptors
35. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
36. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
37. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways
38. Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells
39. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells
40. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: Novel mechanism for hif-1-mediated vascular endothelial growth factor expression
41. Effect of PAI-1 antisense RNA on vascular endothelial growth factor expression in aorta smooth muscle cells cultured in vitro
42. Vascular endothelial growth factor as a target for cancer gene therapy
43. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene
44. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
45. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer
46. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line
47. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
48. Clinical study on surgical treatment of esophageal carcinoma in patients after subtotal gastrectomy
49. Radiotherapy of 180 cases of operable esophageal carcinoma
50. Radiotherapy of double primary esophageal carcinoma
51. Expression of interleukin 1 Deng LY converting enzyme in 5-FU induced apoptosis in esophageal carcinoma cells
52. The study of trace elements in the hair of patients with esophageal carcinoma in high risk area
53. Quantitative detection of nitric oxide (NO) in apoptosis of esophageal carcinoma cell induced by arsenite
54. The expression of COX-2 in esophageal carcinoma and its relation to clinicopathologic characteristic
55. Cloning and expression of HPV16 L-2 DNA from esophageal carcinoma in E. coli
56. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen in esophageal carcinoma and pre cancerous lesions
57. Deletion of p16 gene at a high frequency in esophageal carcinoma
58. Association of CD15 antigen expression with cathepsin D in esophageal carcinoma tissues
59. P21WAF1 gene expression with p53 mutation in esophageal carcinoma
60. Deletion of p16 gene at a high frequency in esophageal carcinoma
61. Alterations of nitric oxide in apoptosis of esophageal carcinoma cells induced by arsenite
62. Morphologic study on apoptosis of esophageal carcinoma cell line induced by arsenic trioxide
63. Expression of CD44v6 in esophageal carcinoma and its clinical significance
64. Radioprotection of radiated auto blood transfusion on patients with esophageal carcinoma
65. Comparative assessment of three prosthesis types of palliative intubation for late stage esophageal carcinoma